Advertisement
GOSS vs ONC
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Hold and ONC is a Buy.
Momentum Indicator for GOSS turns negative, indicating new downward trend
GOSS saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In 72 of the 79 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 48 cases where GOSS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GOSS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
GOSS broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GOSS entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GOSS just turned positive on October 12, 2026. Looking at past instances where GOSS's MACD turned positive, the stock continued to rise in 33 of 38 cases over the following month. The odds of a continued upward trend are 87%.
Following a +16.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where GOSS advanced for three days, in 215 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.636) is normal, around the industry mean (2.788). P/E Ratio (-0.230) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (0.666) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. GOSS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GOSS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ONC in -4.14% downward trend, sliding for three consecutive days on November 03, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ONC declined for three days, in 239 of 320 cases, the price declined further within the following month. The odds of a continued downward trend are 75%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ONC moved out of overbought territory on October 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 26 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 64 cases where ONC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on ONC as a result. In 60 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for ONC just turned positive on November 05, 2026. Looking at past instances where ONC's MACD turned positive, the stock continued to rise in 36 of 49 cases over the following month. The odds of a continued upward trend are 73%.
ONC moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ONC crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONC advanced for three days, in 224 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
ONC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 192 of 260 cases where ONC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ONC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.898) is normal, around the industry mean (2.788). P/E Ratio (69.566) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.776) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (6.553) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
GOSS | ONC | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 28 Undervalued | 94 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 92 | |
SMR RATING 1..100 | 100 | 58 | |
PRICE GROWTH RATING 1..100 | 84 | 42 | |
P/E GROWTH RATING 1..100 | 26 | 97 | |
SEASONALITY SCORE 1..100 | 45 | 49 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GOSS's Valuation (28) in the Pharmaceuticals Major industry is significantly better than the same rating for ONC (94) in the Biotechnology industry. This means that GOSS’s stock grew significantly faster than ONC’s over the last 12 months.
ONC's Profit vs Risk Rating (92) in the Biotechnology industry is in the same range as GOSS (100) in the Pharmaceuticals Major industry. This means that ONC’s stock grew similarly to GOSS’s over the last 12 months.
ONC's SMR Rating (58) in the Biotechnology industry is somewhat better than the same rating for GOSS (100) in the Pharmaceuticals Major industry. This means that ONC’s stock grew somewhat faster than GOSS’s over the last 12 months.
ONC's Price Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for GOSS (84) in the Pharmaceuticals Major industry. This means that ONC’s stock grew somewhat faster than GOSS’s over the last 12 months.
GOSS's P/E Growth Rating (26) in the Pharmaceuticals Major industry is significantly better than the same rating for ONC (97) in the Biotechnology industry. This means that GOSS’s stock grew significantly faster than ONC’s over the last 12 months.
| GOSS | ONC | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 68% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 78% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| MACD ODDS (%) | 2 days ago 87% | 2 days ago 73% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 75% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 71% |
| Advances ODDS (%) | 10 days ago 84% | 2 days ago 74% |
| Declines ODDS (%) | 4 days ago 89% | 4 days ago 75% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 74% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GOSS’s FA Score shows that 2 FA rating(s) are green while ONC’s FA Score has 0 green FA rating(s).
- GOSS’s FA Score: 2 green, 3 red.
- ONC’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GOSS’s TA Score shows that 2 TA indicator(s) are bullish while ONC’s TA Score has 8 bullish TA indicator(s).
- GOSS’s TA Score: 2 bullish, 5 bearish.
- ONC’s TA Score: 8 bullish, 2 bearish.
Price Growth
GOSS (@Biotechnology) experienced а -11.88% price change this week, while ONC (@Biotechnology) price change was +4.22% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -3.91%, and the average quarterly price growth was -15.16%.
Reported Earning Dates
GOSS is expected to report earnings on Mar 12, 2027.
ONC is expected to report earnings on Mar 31, 2027.
Industries' Descriptions
@Biotechnology (+7.94% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
GOSS and
Correlation & Price change
A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with LITS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then LITS could also see price increases.
| Ticker / NAME | Correlation To GOSS | 1D Price Change % | ||
|---|---|---|---|---|
| GOSS | 100% | -5.33% | ||
| LITS - GOSS | 46% Loosely correlated | -9.99% | ||
| APVO - GOSS | 41% Loosely correlated | -7.30% | ||
| IDYA - GOSS | 38% Loosely correlated | -5.28% | ||
| XNCR - GOSS | 38% Loosely correlated | -2.80% | ||
| SYRE - GOSS | 38% Loosely correlated | -2.47% | ||
More | ||||
ONC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ONC has been loosely correlated with VRTX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ONC jumps, then VRTX could also see price increases.
| Ticker / NAME | Correlation To ONC | 1D Price Change % | ||
|---|---|---|---|---|
| ONC | 100% | +2.51% | ||
| VRTX - ONC | 39% Loosely correlated | -1.19% | ||
| HALO - ONC | 38% Loosely correlated | -5.66% | ||
| AXON - ONC | 37% Loosely correlated | -9.81% | ||
| GOSS - ONC | 35% Loosely correlated | -5.33% | ||
| ARGX - ONC | 35% Loosely correlated | -3.93% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SHNY | 7.35 | 0.17 | +2.37% |
| MicroSectors Gold 3X Leveraged ETNs (SHNY) | |||
| AV | 26.49 | N/A | N/A |
| Corgi Aerospace & Commercial Aviation ETF (AV) | |||
| USNZ | 48.54 | N/A | N/A |
| Xtrackers Net Zero Pathway Paris Aligned US Equity ETF (USNZ) | |||
| TLTI | 43.25 | -0.09 | -0.21% |
| NEOS Enhanced Income 20+ Year Treasury Bond ETF (TLTI) | |||
| IMCV | 98.43 | -2.29 | -2.27% |
| iShares Morningstar Mid-Cap Value ETF (IMCV) | |||